Cholecystectomy is associated with higher risk of recurrence after microwave ablation of hepatocellular carcinoma: a propensity score matching analysis

被引:14
作者
Yang, Hongcai [1 ,2 ]
Yang, Yi [3 ]
Dou, Jianping [2 ]
Cui, Rui [2 ]
Cheng, Zhigang [2 ]
Han, Zhiyu [2 ]
Liu, Fangyi [2 ]
Yu, Xiaoling [2 ]
Zhou, Xiang [3 ]
Yu, Jie [2 ]
Liang, Ping [1 ,2 ]
机构
[1] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Intervent Ultrasound, Beijing 100853, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Intervent Therapy, Beijing 100021, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
Cholecystectomy; microwave ablation; hepatocellular carcinoma; propensity score matching; GAMMA-GLUTAMYL-TRANSFERASE; RADIOFREQUENCY ABLATION; CANCER INCIDENCE; LIVER; SURVIVAL; EPIDEMIOLOGY; INFLAMMATION; GALLBLADDER; GALLSTONES; GUIDELINES;
D O I
10.20892/j.issn.2095-3941.2019.0246
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To explore the association between cholecystectomy and the prognostic outcomes of patients with hepatocellular carcinoma (HCC) who underwent microwave ablation (MWA). Methods: Patients with HCC (n = 921) who underwent MWA were included and divided into cholecystectomy (n = 114) and non-cholecystectomy groups (n = 807). After propensity score matching (PSM) at a 1:2 ratio, overall survival (OS) and disease-free survival (DFS) rates were analyzed to compare prognostic outcomes between the cholecystectomy (n = 114) and non-cholecystectomy groups (n = 228). Univariate and multivariate Cox analyses were performed to assess potential risk factors for OS and DFS. Major complications were also compared between the groups. Results: After matching, no significant differences between groups were observed in baseline characteristics. The 1-, 3-, and 5-year OS rates were 96.5%, 82.1%, and 67.1% in the cholecystectomy group, and 97.4%, 85.2%, and 74.4% in the non-cholecystectomy group (P = 0.396); the 1-, 3-, and 5-year DFS rates were 58.4%, 34.5%, and 26.6% in the cholecystectomy group, and 73.6%, 44.7%, and 32.2% in the non-cholecystectomy group (P = 0.026), respectively. The intrahepatic distant recurrence rate in the cholecystectomy group was significantly higher than that in the non-cholecystectomy group (P = 0.026), and the local tumor recurrence and extrahepatic recurrence rates did not significantly differ between the groups (P = 0.609 and P = 0.879). Multivariate analysis revealed that cholecystectomy (HR = 1.364, 95% CI 1.023-1.819, P = 0.035), number of tumors (2 vs. 1: HR = 2.744, 95% CI 1.925-3.912, P < 0.001; 3 vs. 1: HR = 3.411, 95% CI 2.021-5.759, P < 0.001), and gamma-GT levels (HR = 1.003, 95% CI 1.000-1.006, P < 0.024) were independent risk factors for DFS. The best gamma-GT level cut-off value for predicting median DFS was 39.6 U/L (area under the curve = 0.600, P < 0.05). A positive correlation was observed between cholecystectomy and gamma-GT level (r = 0.108, 95% CI -0.001-0.214, P = 0.047). Subgroup analysis showed that the DFS rates were significantly higher in the non-cholecystectomy group than the cholecystectomy group when gamma-GT >= 39.6 U/L (P = 0.044). The 5-, 10-, 15-, 20-, and 25-year recurrence rates from the time of cholecystectomy were 2.63%, 21.93%, 42.11%, 58.77%, and 65.79%, respectively. A significant positive correlation was observed between cholecystectomy and the time from cholecystectomy to recurrence (r = 0.205, 95% CI 0.016-0.379, P = 0.029). There were no significant differences in complications between groups (P = 0.685). Conclusions: Patients with HCC who underwent cholecystectomy were more likely to develop intrahepatic distant recurrence after MWA, an outcome probably associated with increased gamma-GT levels. Moreover, the recurrence rates increased with time.
引用
收藏
页码:478 / 491
页数:14
相关论文
共 37 条
  • [1] Ahmed M, 2014, RADIOLOGY, V273, P241, DOI [10.1148/radiol.14132958, 10.1016/j.jvir.2014.08.027]
  • [2] FoxC1: Novel Regulator of Inflammation-Induced Metastasis in Hepatocellular Carcinoma
    Aravalli, Rajagopal N.
    Greten, Tim F.
    [J]. GASTROENTEROLOGY, 2015, 149 (04) : 861 - 863
  • [3] NCCN Guidelines® Insights Hepatobiliary Cancers, Version 1.2017 Featured Updates to the NCCN Guidelines
    Benson, Al B., III
    D'Angelica, Michael I.
    Abbott, Daniel E.
    Abrams, Thomas A.
    Alberts, Steven R.
    Saenz, Daniel Anaya
    Are, Chandrakanth
    Brown, Daniel B.
    Chang, Daniel T.
    Covey, Anne M.
    Hawkins, William
    Iyer, Renuka
    Jacob, Rojymon
    Karachristos, Andrea
    Kelley, R. Kate
    Kim, Robin
    Palta, Manisha
    Park, James O.
    Sahai, Vaibhav
    Schefter, Tracey
    Schmidt, Carl
    Sicklick, Jason K.
    Singh, Gagandeep
    Sohal, Davendra
    Stein, Stacey
    Tian, G. Gary
    Vauthey, Jean-Nicolas
    Venook, Alan P.
    Zhu, Andrew X.
    Hoffmann, Karin G.
    Darlow, Susan
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (05): : 563 - 573
  • [4] Local recurrence after laparoscopic radiofrequency ablation of liver tumors: An analysis of 1032 tumors
    Berber, Eren
    Siperstein, Allan
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (10) : 2757 - 2764
  • [5] Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference
    Bruix, J
    Sherman, M
    Llovet, JM
    Beaugrand, M
    Lencioni, R
    Burroughs, AK
    Christensen, E
    Pagliaro, L
    Colombo, M
    Rodés, J
    [J]. JOURNAL OF HEPATOLOGY, 2001, 35 (03) : 421 - 430
  • [6] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [7] CSENDES A, 1979, GASTROENTEROLOGY, V77, P1203
  • [8] Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
    El-Serag, Hashem B.
    Rudolph, Lenhard
    [J]. GASTROENTEROLOGY, 2007, 132 (07) : 2557 - 2576
  • [9] European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.ejca.2011.12.021, 10.1016/j.jhep.2011.12.001]
  • [10] Cholelithiasis, cholecystectomy and risk of hepatocellular carcinoma: A meta-analysis
    Guo, Lingyun
    Mao, Jie
    Li, Yumin
    Jiao, Zuoyi
    Guo, Jiwu
    Zhang, Junqiang
    Zhao, Jun
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2014, 10 (04) : 834 - 838